HRCM
CRL icon

Hood River Capital Management’s Charles River Laboratories CRL Stock Holding History

Hood River Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,226
Closed -$3.97M – 149
2024
Q2 		$3.97M Buy
+19,226
New +$4.36M 0.08% 122
2022
Q4 		– Sell
-5,249
Closed -$1.03M – 111
2022
Q3 		$1.03M Hold
5,249
– – 0.04% 94
2022
Q2 		$1.12M Buy
5,249
+42
+0.8% +$10.3K 0.04% 99
2022
Q1 		$1.48M Sell
5,207
-28
-0.5% -$8.63K 0.05% 96
2021
Q4 		$1.97M Hold
5,235
– – 0.06% 92
2021
Q3 		$2.16M Hold
5,235
– – 0.07% 98
2021
Q2 		$1.94M Buy
5,235
+1,636
+45% +$546K 0.06% 99
2021
Q1 		$1.04M Sell
3,599
-170,721
-98% -$47.5M 0.03% 103
2020
Q4 		$43.6M Sell
174,320
-137,720
-44% -$32.8M 1.44% 20
2020
Q3 		$70.7M Sell
312,040
-31,378
-9% -$6.51M 3.07% 4
2020
Q2 		$59.9M Sell
343,418
-38,185
-10% -$6.09M 2.68% 6
2020
Q1 		$48.2M Buy
381,603
+35,157
+10% +$5.27M 2.75% 7
2019
Q4 		$52.9M Buy
346,446
+19,494
+6% +$2.7M 2.29% 6
2019
Q3 		$43.3M Sell
326,952
-28,839
-8% -$3.87M 2.21% 8
2019
Q2 		$50.5M Buy
355,791
+29,616
+9% +$4.02M 2.37% 6
2019
Q1 		$47.4M Buy
326,175
+14,243
+5% +$1.87M 2.38% 5
2018
Q4 		$35.3M Buy
311,932
+39,868
+15% +$4.99M 2.08% 6
2018
Q3 		$36.6M Buy
272,064
+67,187
+33% +$8.29M 1.62% 17
2018
Q2 		$23M Buy
204,877
+7,990
+4% +$864K 1.18% 32
2018
Q1 		$21M Sell
196,887
-50,319
-20% -$5.42M 1.18% 29
2017
Q4 		$27.1M Sell
247,206
-22,381
-8% -$2.44M 1.57% 18
2017
Q3 		$29.1M Buy
269,587
+5,770
+2% +$593K 1.85% 13
2017
Q2 		$26.7M Buy
263,817
+6,000
+2% +$552K 1.84% 13
2017
Q1 		$23.2M Sell
257,817
-968
-0.4% -$82.2K 1.74% 14
2016
Q4 		$19.7M Sell
258,785
-15,421
-6% -$1.17M 1.72% 14
2016
Q3 		$22.9M Buy
274,206
+88,813
+48% +$7.44M 2.34% 8
2016
Q2 		$15.3M Buy
185,393
+13,943
+8% +$1.15M 2.05% 8
2016
Q1 		$13M Sell
171,450
-34,369
-17% -$2.54M 1.74% 14
2015
Q4 		$16.5M Buy
205,819
+70,583
+52% +$5.09M 2.12% 9
2015
Q3 		$8.59M Buy
+135,236
New +$9.71M 1.19% 39

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Hood River Capital Management's CRL Position: Q3 2024 in Review

Hood River Capital Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 19,226 shares — an estimated $3.97M sold.

Hood River Capital Management first reported a position in CRL in Q3 2015 and held it in 30 quarters. The position peaked at $70.7M in Q3 2020. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Hood River Capital Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Hood River Capital Management sold 19,226 Charles River Laboratories shares in Q3 2024, an estimated $3.97M.
  • Hood River Capital Management first reported a position in Charles River Laboratories in Q3 2015 and held it in 30 quarters.
  • Hood River Capital Management's Charles River Laboratories position peaked at $70.7M in Q3 2020.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Hood River Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.